CA2306985A1 - Novel use of compounds for anti-pruritic activity - Google Patents

Novel use of compounds for anti-pruritic activity Download PDF

Info

Publication number: CA2306985A1
Authority: CA; Canada
Prior art keywords: xanthine; compound; cyclopropylmethyl; butyl; nitro
Prior art date: 1997-10-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002306985A

Other languages

English (en)

French (fr)

Inventor

Siegfried Benjamin Christensen Iv

Don E. Griswold

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

SmithKline Beecham Corp

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-10-17

Filing date

1998-10-16

Publication date

1999-04-29

1998-10-16 Application filed by Individual filed Critical Individual

1999-04-29 Publication of CA2306985A1 publication Critical patent/CA2306985A1/en

Status Abandoned legal-status Critical Current

Links

150000001875 compounds Chemical class 0.000 title claims description 72
230000001139 anti-pruritic effect Effects 0.000 title claims description 8
238000000034 method Methods 0.000 claims description 35
150000003839 salts Chemical class 0.000 claims description 19
208000003251 Pruritus Diseases 0.000 claims description 13
241000124008 Mammalia Species 0.000 claims description 10
229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims description 8
125000000217 alkyl group Chemical group 0.000 claims description 8
239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims description 8
KSPYMJJKQMWWNB-UHFFFAOYSA-N cipamfylline Chemical compound O=C1N(CC2CC2)C(=O)C=2NC(N)=NC=2N1CC1CC1 KSPYMJJKQMWWNB-UHFFFAOYSA-N 0.000 claims description 7
239000001257 hydrogen Substances 0.000 claims description 6
229910052739 hydrogen Inorganic materials 0.000 claims description 6
125000004448 alkyl carbonyl group Chemical group 0.000 claims description 5
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 5
125000000623 heterocyclic group Chemical group 0.000 claims description 5
125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 5
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
125000005843 halogen group Chemical group 0.000 claims description 3
229910052757 nitrogen Inorganic materials 0.000 claims description 3
DAHOPKGGXGFYEW-UHFFFAOYSA-N 1,3-bis(cyclohexylmethyl)-8-piperidin-1-yl-7h-purine-2,6-dione Chemical compound C1=2N=C(N3CCCCC3)NC=2C(=O)N(CC2CCCCC2)C(=O)N1CC1CCCCC1 DAHOPKGGXGFYEW-UHFFFAOYSA-N 0.000 claims description 2
INEZLVVKMUWARI-UHFFFAOYSA-N 1,3-bis(cyclopropylmethyl)-8-morpholin-4-yl-7h-purine-2,6-dione Chemical compound C1=2N=C(N3CCOCC3)NC=2C(=O)N(CC2CC2)C(=O)N1CC1CC1 INEZLVVKMUWARI-UHFFFAOYSA-N 0.000 claims description 2
UFAQFYMNIFOKGO-UHFFFAOYSA-N 1,3-bis(cyclopropylmethyl)-8-piperidin-1-yl-7h-purine-2,6-dione Chemical compound C1=2N=C(N3CCCCC3)NC=2C(=O)N(CC2CC2)C(=O)N1CC1CC1 UFAQFYMNIFOKGO-UHFFFAOYSA-N 0.000 claims description 2
AGCQOIRZOOICOR-UHFFFAOYSA-N 1,3-bis(cyclopropylmethyl)-8-pyrrolidin-1-yl-7h-purine-2,6-dione Chemical compound C1=2N=C(N3CCCC3)NC=2C(=O)N(CC2CC2)C(=O)N1CC1CC1 AGCQOIRZOOICOR-UHFFFAOYSA-N 0.000 claims description 2
NODRXLCGHIPPNV-UHFFFAOYSA-N 1,3-dibutyl-8-chloro-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C(=O)N(CCCC)C2=C1NC(Cl)=N2 NODRXLCGHIPPNV-UHFFFAOYSA-N 0.000 claims description 2
IWJJMAURPLFEJI-UHFFFAOYSA-N 1,3-dibutyl-8-piperidin-1-yl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCCC)C(=O)N(CCCC)C=2N=C1N1CCCCC1 IWJJMAURPLFEJI-UHFFFAOYSA-N 0.000 claims description 2
ZIBJHVUQUMZJBQ-UHFFFAOYSA-N 1,3-dibutyl-8-pyrrolidin-1-yl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCCC)C(=O)N(CCCC)C=2N=C1N1CCCC1 ZIBJHVUQUMZJBQ-UHFFFAOYSA-N 0.000 claims description 2
WQBKKJIJEGGRNX-UHFFFAOYSA-N 8-amino-1,3-bis(cyclobutylmethyl)-7h-purine-2,6-dione Chemical compound O=C1N(CC2CCC2)C(=O)C=2NC(N)=NC=2N1CC1CCC1 WQBKKJIJEGGRNX-UHFFFAOYSA-N 0.000 claims description 2
FZMLHPFGNMRBNM-UHFFFAOYSA-N 8-amino-1,3-bis(cyclohexylmethyl)-7h-purine-2,6-dione Chemical compound O=C1N(CC2CCCCC2)C(=O)C=2NC(N)=NC=2N1CC1CCCCC1 FZMLHPFGNMRBNM-UHFFFAOYSA-N 0.000 claims description 2
MVILGRWJMAJOGO-UHFFFAOYSA-N 8-amino-1,3-bis(cyclopentylmethyl)-7h-purine-2,6-dione Chemical compound O=C1N(CC2CCCC2)C(=O)C=2NC(N)=NC=2N1CC1CCCC1 MVILGRWJMAJOGO-UHFFFAOYSA-N 0.000 claims description 2
LCPGQPIZMXWYDE-UHFFFAOYSA-N 8-amino-1,3-dibutyl-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C(=O)N(CCCC)C2=C1NC(N)=N2 LCPGQPIZMXWYDE-UHFFFAOYSA-N 0.000 claims description 2
ONLIBHWZVVTZQO-UHFFFAOYSA-N 8-amino-1,3-dicyclopropyl-7h-purine-2,6-dione Chemical compound O=C1N(C2CC2)C(=O)C=2NC(N)=NC=2N1C1CC1 ONLIBHWZVVTZQO-UHFFFAOYSA-N 0.000 claims description 2
CCCFLROKQFJCMT-UHFFFAOYSA-N 8-bromo-1,3-bis(cyclohexylmethyl)-7h-purine-2,6-dione Chemical compound O=C1N(CC2CCCCC2)C(=O)C=2NC(Br)=NC=2N1CC1CCCCC1 CCCFLROKQFJCMT-UHFFFAOYSA-N 0.000 claims description 2
BOZFJXDDBMXHQB-UHFFFAOYSA-N 8-bromo-1,3-dibutyl-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C(=O)N(CCCC)C2=C1NC(Br)=N2 BOZFJXDDBMXHQB-UHFFFAOYSA-N 0.000 claims description 2
QZMLAWVVWTZRLF-UHFFFAOYSA-N 8-chloro-1,3-bis(cyclopropylmethyl)-7h-purine-2,6-dione Chemical compound O=C1N(CC2CC2)C(=O)C=2NC(Cl)=NC=2N1CC1CC1 QZMLAWVVWTZRLF-UHFFFAOYSA-N 0.000 claims description 2
FOGDEWDBZWEMOH-UHFFFAOYSA-N 8-chloro-1,3-dicyclohexyl-7h-purine-2,6-dione Chemical compound O=C1N(C2CCCCC2)C(=O)C=2NC(Cl)=NC=2N1C1CCCCC1 FOGDEWDBZWEMOH-UHFFFAOYSA-N 0.000 claims description 2
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
FHHJDLUVUSSPDK-UHFFFAOYSA-N n-(1,3-dibutyl-2,6-dioxo-7h-purin-8-yl)acetamide Chemical compound O=C1N(CCCC)C(=O)N(CCCC)C2=C1NC(NC(C)=O)=N2 FHHJDLUVUSSPDK-UHFFFAOYSA-N 0.000 claims description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 2
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
150000003431 steroids Chemical class 0.000 claims description 2
239000003908 antipruritic agent Substances 0.000 claims 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
FBWOCBWJZRIJBU-UHFFFAOYSA-N 1,3-bis(cyclobutylmethyl)-8-nitro-7h-purine-2,6-dione Chemical compound O=C1N(CC2CCC2)C(=O)C=2NC([N+](=O)[O-])=NC=2N1CC1CCC1 FBWOCBWJZRIJBU-UHFFFAOYSA-N 0.000 claims 1
YWIDXLMXWUIXOJ-UHFFFAOYSA-N 1,3-bis(cyclohexylmethyl)-8-nitro-7h-purine-2,6-dione Chemical compound O=C1N(CC2CCCCC2)C(=O)C=2NC([N+](=O)[O-])=NC=2N1CC1CCCCC1 YWIDXLMXWUIXOJ-UHFFFAOYSA-N 0.000 claims 1
LZNXLJQGCRQYDT-UHFFFAOYSA-N 1,3-bis(cyclopentylmethyl)-8-nitro-7h-purine-2,6-dione Chemical compound O=C1N(CC2CCCC2)C(=O)C=2NC([N+](=O)[O-])=NC=2N1CC1CCCC1 LZNXLJQGCRQYDT-UHFFFAOYSA-N 0.000 claims 1
KXZCOUISCHFBJW-UHFFFAOYSA-N 1,3-bis(cyclopropylmethyl)-8-nitro-7h-purine-2,6-dione Chemical compound O=C1N(CC2CC2)C(=O)C=2NC([N+](=O)[O-])=NC=2N1CC1CC1 KXZCOUISCHFBJW-UHFFFAOYSA-N 0.000 claims 1
PEUMRAZSOJOADF-UHFFFAOYSA-N 1,3-dibutyl-8-nitro-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C(=O)N(CCCC)C2=C1NC([N+]([O-])=O)=N2 PEUMRAZSOJOADF-UHFFFAOYSA-N 0.000 claims 1
LYNPMBCGTLJEDK-UHFFFAOYSA-N 1,3-dicyclohexyl-8-nitro-7h-purine-2,6-dione Chemical compound O=C1N(C2CCCCC2)C(=O)C=2NC([N+](=O)[O-])=NC=2N1C1CCCCC1 LYNPMBCGTLJEDK-UHFFFAOYSA-N 0.000 claims 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
201000010099 disease Diseases 0.000 abstract description 6
-1 8-substituted xanthines Chemical class 0.000 abstract description 5
208000035475 disorder Diseases 0.000 abstract description 3
230000001823 pruritic effect Effects 0.000 abstract description 3
230000000069 prophylactic effect Effects 0.000 abstract description 2
238000002560 therapeutic procedure Methods 0.000 abstract 1
238000011282 treatment Methods 0.000 description 21
239000000203 mixture Substances 0.000 description 17
LRFVTYWOQMYALW-UHFFFAOYSA-N Xanthine Natural products O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 14
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 12
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
238000009472 formulation Methods 0.000 description 11
239000000243 solution Substances 0.000 description 11
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
239000003795 chemical substances by application Substances 0.000 description 9
238000002360 preparation method Methods 0.000 description 9
239000004480 active ingredient Substances 0.000 description 8
125000000753 cycloalkyl group Chemical group 0.000 description 8
229940075420 xanthine Drugs 0.000 description 8
239000003937 drug carrier Substances 0.000 description 7
230000000694 effects Effects 0.000 description 7
239000007788 liquid Substances 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
229940114079 arachidonic acid Drugs 0.000 description 6
235000021342 arachidonic acid Nutrition 0.000 description 6
239000000969 carrier Substances 0.000 description 6
239000003921 oil Substances 0.000 description 6
235000019198 oils Nutrition 0.000 description 6
239000007787 solid Substances 0.000 description 6
239000000725 suspension Substances 0.000 description 6
238000007796 conventional method Methods 0.000 description 5
239000002552 dosage form Substances 0.000 description 5
239000007903 gelatin capsule Substances 0.000 description 5
239000004615 ingredient Substances 0.000 description 5
125000006413 ring segment Chemical group 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
201000004624 Dermatitis Diseases 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
239000012458 free base Substances 0.000 description 4
235000011187 glycerol Nutrition 0.000 description 4
239000006210 lotion Substances 0.000 description 4
210000003491 skin Anatomy 0.000 description 4
239000006188 syrup Substances 0.000 description 4
235000020357 syrup Nutrition 0.000 description 4
238000011200 topical administration Methods 0.000 description 4
230000000699 topical effect Effects 0.000 description 4
235000003911 Arachis Nutrition 0.000 description 3
244000105624 Arachis hypogaea Species 0.000 description 3
241000282412 Homo Species 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
239000000443 aerosol Substances 0.000 description 3
230000000844 anti-bacterial effect Effects 0.000 description 3
239000003899 bactericide agent Substances 0.000 description 3
239000002775 capsule Substances 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
229910052736 halogen Inorganic materials 0.000 description 3
150000002367 halogens Chemical group 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
238000007918 intramuscular administration Methods 0.000 description 3
238000002156 mixing Methods 0.000 description 3
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
238000006748 scratching Methods 0.000 description 3
230000002393 scratching effect Effects 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
238000012360 testing method Methods 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
206010012438 Dermatitis atopic Diseases 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
108010044467 Isoenzymes Proteins 0.000 description 2
108010003541 Platelet Activating Factor Proteins 0.000 description 2
201000004681 Psoriasis Diseases 0.000 description 2
238000000692 Student's t-test Methods 0.000 description 2
230000004308 accommodation Effects 0.000 description 2
230000003110 anti-inflammatory effect Effects 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
238000003556 assay Methods 0.000 description 2
201000008937 atopic dermatitis Diseases 0.000 description 2
208000010668 atopic eczema Diseases 0.000 description 2
230000003542 behavioural effect Effects 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
239000003240 coconut oil Substances 0.000 description 2
235000019864 coconut oil Nutrition 0.000 description 2
239000006071 cream Substances 0.000 description 2
125000001316 cycloalkyl alkyl group Chemical group 0.000 description 2
239000003814 drug Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
230000000763 evoking effect Effects 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000000417 fungicide Substances 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
230000028709 inflammatory response Effects 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
230000002452 interceptive effect Effects 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000000865 liniment Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
238000010172 mouse model Methods 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
239000002674 ointment Substances 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000006072 paste Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
230000002335 preservative effect Effects 0.000 description 2
238000011321 prophylaxis Methods 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
238000007910 systemic administration Methods 0.000 description 2
239000003826 tablet Substances 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
KSEJZTWORQXILM-UHFFFAOYSA-N 2-(4-methylsulfinylphenyl)-3-pyridin-4-yl-6,7-dihydro-5h-pyrrolo[1,2-a]imidazole Chemical compound C1=CC(S(=O)C)=CC=C1C1=C(C=2C=CN=CC=2)N2CCCC2=N1 KSEJZTWORQXILM-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
244000144725 Amygdalus communis Species 0.000 description 1
235000011437 Amygdalus communis Nutrition 0.000 description 1
206010003645 Atopy Diseases 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
206010012442 Dermatitis contact Diseases 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
239000004166 Lanolin Substances 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
239000004909 Moisturizer Substances 0.000 description 1
229920000715 Mucilage Polymers 0.000 description 1
240000007817 Olea europaea Species 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
235000004443 Ricinus communis Nutrition 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
102000003141 Tachykinin Human genes 0.000 description 1
241000906446 Theraps Species 0.000 description 1
206010054094 Tumour necrosis Diseases 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
208000002029 allergic contact dermatitis Diseases 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
235000020224 almond Nutrition 0.000 description 1
239000003708 ampul Substances 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
239000003945 anionic surfactant Substances 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
239000003093 cationic surfactant Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
229960002152 chlorhexidine acetate Drugs 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
235000020415 coconut juice Nutrition 0.000 description 1
238000004040 coloring Methods 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000006196 drop Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000001035 drying Methods 0.000 description 1
150000002066 eicosanoids Chemical class 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
210000003979 eosinophil Anatomy 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000012530 fluid Substances 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
229940074045 glyceryl distearate Drugs 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
210000003630 histaminocyte Anatomy 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
229910010272 inorganic material Inorganic materials 0.000 description 1
239000011147 inorganic material Substances 0.000 description 1
125000002346 iodo group Chemical group I* 0.000 description 1
208000001875 irritant dermatitis Diseases 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000008101 lactose Substances 0.000 description 1
235000019388 lanolin Nutrition 0.000 description 1
229940039717 lanolin Drugs 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000007726 management method Methods 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
229940071648 metered dose inhaler Drugs 0.000 description 1
201000002266 mite infestation Diseases 0.000 description 1
230000001333 moisturizer Effects 0.000 description 1
125000002757 morpholinyl group Chemical group 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229920001206 natural gum Polymers 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000035515 penetration Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
125000003386 piperidinyl group Chemical group 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 description 1
229940127293 prostanoid Drugs 0.000 description 1
150000003814 prostanoids Chemical class 0.000 description 1
125000000719 pyrrolidinyl group Chemical group 0.000 description 1
MHOZZUICEDXVGD-UHFFFAOYSA-N pyrrolo[2,3-d]imidazole Chemical compound C1=NC2=CC=NC2=N1 MHOZZUICEDXVGD-UHFFFAOYSA-N 0.000 description 1
230000004044 response Effects 0.000 description 1
206010039083 rhinitis Diseases 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
239000000344 soap Substances 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
108060008037 tachykinin Proteins 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
239000012049 topical pharmaceutical composition Substances 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
239000001993 wax Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1
210000002268 wool Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

CA002306985A 1997-10-17 1998-10-16 Novel use of compounds for anti-pruritic activity Abandoned CA2306985A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US6374697P	1997-10-17	1997-10-17
US60/063,746		1997-10-17
PCT/US1998/021886 WO1999020280A1 (en)	1997-10-17	1998-10-16	Novel use of compounds for anti-pruritic activity

Publications (1)

Publication Number	Publication Date
CA2306985A1 true CA2306985A1 (en)	1999-04-29

Family

ID=22051225

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002306985A Abandoned CA2306985A1 (en)	1997-10-17	1998-10-16	Novel use of compounds for anti-pruritic activity

Country Status (18)

Country	Link
EP (1)	EP1030666A4 (tr)
JP (1)	JP2001520196A (tr)
KR (1)	KR20010031149A (tr)
CN (1)	CN1306426A (tr)
AR (1)	AR015966A1 (tr)
AU (1)	AU740875B2 (tr)
BR (1)	BR9814080A (tr)
CA (1)	CA2306985A1 (tr)
CO (1)	CO4810374A1 (tr)
CZ (1)	CZ20001376A3 (tr)
HU (1)	HUP0003792A3 (tr)
IL (1)	IL135581A0 (tr)
NO (1)	NO20001847D0 (tr)
NZ (1)	NZ503551A (tr)
PL (1)	PL341062A1 (tr)
TR (1)	TR200001040T2 (tr)
WO (1)	WO1999020280A1 (tr)
ZA (1)	ZA989450B (tr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8492543B2 (en)	2007-08-17	2013-07-23	Eisai R&D Management Co., Ltd.	Method for producing quinazoline derivative
TWI404709B (zh) *	2006-02-21	2013-08-11	Eisai R&D Man Co Ltd	4- (3-benzamidophenyl) -6,7-dimethoxy-2-methylamine quinazoline derivatives
US8530654B2 (en)	2007-02-16	2013-09-10	Eisai R&D Management Co., Ltd.	Crystals, amorphous substances or salts of methyl N-[3-(6,7-dimethoxy-2-methylaminoquinazolin-4-yl) phenyl] terephthalamic acid

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20030070150A (ko)	2001-01-31	2003-08-27	화이자 프로덕츠 인크.	Ｐｄｅ4 이소자임 억제제로서 유용한 에테르 유도체
US7250518B2 (en)	2001-01-31	2007-07-31	Pfizer Inc.	Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
CZ20031903A3 (cs)	2001-01-31	2004-07-14	Pfizer Products Inc.	Amidové deriváty thiazolyl-, oxazolyl-, pyrrolyl- a imidazolyl karboxylových kyselin užitečné jako inhibitory isozymů PDE4
WO2002060875A1 (en)	2001-01-31	2002-08-08	Pfizer Products Inc.	Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes
US20030175314A1 (en) *	2001-11-19	2003-09-18	Didriksen Erik Johannes	Pharmaceutical composition for dermal application
EP1647274A4 (en) *	2003-07-17	2008-12-10	Ono Pharmaceutical Co	REMEDY AGAINST PRURIT COMPRISING A PIPERIDINE DERIVATIVE AS AN ACTIVE INGREDIENT
WO2005053672A1 (ja) *	2003-12-04	2005-06-16	Santen Pharmaceutical Co., Ltd.	シロミラストまたはその塩を有効成分とする掻痒治療剤
JP2005187458A (ja) *	2003-12-04	2005-07-14	Santen Pharmaceut Co Ltd	シロミラストまたはその塩を有効成分とする掻痒治療剤
CA2556073C (en) *	2004-02-14	2012-01-10	Smithkline Beecham Corporation	8-chloro-1,3-disubstituted xanthine derivatives as hm74a receptor modulators
JP2008137892A (ja) *	2005-03-04	2008-06-19	Eisai Co Ltd	止痒剤
US8143264B2 (en)	2005-08-10	2012-03-27	Glaxosmithkline Llc	Xanthine derivatives as selective HM74A agonists
WO2007097317A1 (ja) *	2006-02-21	2007-08-30	Eisai R & D Management Co., Ltd.	４－（３－ベンゾイルアミノフェニル）－６，７－ジメトキシ－２－メチルアミノキナゾリン誘導体
CN101687819B (zh)	2007-08-17	2013-03-20	卫材R&D管理有限公司	外用剂
US20140121240A1 (en) *	2011-06-28	2014-05-01	Maruho Co., Ltd.	Novel pharmaceutical composition
PT3251675T (pt)	2015-01-30	2021-05-25	Shanton Pharma Pte Ltd	Prevenção ou tratamento de doença de ácido úrico ou gota

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2148170T3 (es) *	1990-12-21	2000-10-16	Beecham Group Plc	Derivados de xantina.
CA2250569C (en) *	1996-03-26	2005-05-10	Byk Gulden Lomberg Chemische Fabrik Gmbh	Novel phenanthridines substituted in the 6 position
DE69717277T2 (de) *	1996-05-15	2003-09-18	Altana Pharma Ag	Imidazopyridine
SI0968211T1 (en) *	1997-03-07	2004-02-29	Altana Pharma Ag	Tetrazole derivatives
SK122199A3 (en) *	1997-03-18	2000-12-11	Basf Ag	Methods and compositions for modulating responsiveness to corticosteroids
AU8106598A (en) *	1997-06-03	1998-12-21	Byk Gulden Lomberg Chemische Fabrik Gmbh	Benzonaphthyridine

1998
- 1998-10-15 AR ARP980105131A patent/AR015966A1/es not_active Application Discontinuation
- 1998-10-16 KR KR1020007004053A patent/KR20010031149A/ko not_active Withdrawn
- 1998-10-16 CO CO98060225A patent/CO4810374A1/es unknown
- 1998-10-16 JP JP2000516677A patent/JP2001520196A/ja not_active Withdrawn
- 1998-10-16 ZA ZA989450A patent/ZA989450B/xx unknown
- 1998-10-16 NZ NZ503551A patent/NZ503551A/en unknown
- 1998-10-16 WO PCT/US1998/021886 patent/WO1999020280A1/en not_active Ceased
- 1998-10-16 CN CN98810066A patent/CN1306426A/zh active Pending
- 1998-10-16 CZ CZ20001376A patent/CZ20001376A3/cs unknown
- 1998-10-16 CA CA002306985A patent/CA2306985A1/en not_active Abandoned
- 1998-10-16 TR TR2000/01040T patent/TR200001040T2/tr unknown
- 1998-10-16 AU AU10938/99A patent/AU740875B2/en not_active Ceased
- 1998-10-16 IL IL13558198A patent/IL135581A0/xx unknown
- 1998-10-16 EP EP98953608A patent/EP1030666A4/en not_active Withdrawn
- 1998-10-16 HU HU0003792A patent/HUP0003792A3/hu unknown
- 1998-10-16 PL PL98341062A patent/PL341062A1/xx unknown
- 1998-10-16 BR BR9814080-9A patent/BR9814080A/pt not_active IP Right Cessation
2000
- 2000-04-10 NO NO20001847A patent/NO20001847D0/no not_active Application Discontinuation

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI404709B (zh) *	2006-02-21	2013-08-11	Eisai R&D Man Co Ltd	4- (3-benzamidophenyl) -6,7-dimethoxy-2-methylamine quinazoline derivatives
US8530654B2 (en)	2007-02-16	2013-09-10	Eisai R&D Management Co., Ltd.	Crystals, amorphous substances or salts of methyl N-[3-(6,7-dimethoxy-2-methylaminoquinazolin-4-yl) phenyl] terephthalamic acid
US8492543B2 (en)	2007-08-17	2013-07-23	Eisai R&D Management Co., Ltd.	Method for producing quinazoline derivative

Also Published As

Publication number	Publication date
NZ503551A (en)	2002-05-31
CO4810374A1 (es)	1999-06-30
WO1999020280A1 (en)	1999-04-29
AU740875B2 (en)	2001-11-15
EP1030666A1 (en)	2000-08-30
ZA989450B (en)	1999-04-19
NO20001847L (no)	2000-04-10
PL341062A1 (en)	2001-03-26
KR20010031149A (ko)	2001-04-16
AU1093899A (en)	1999-05-10
JP2001520196A (ja)	2001-10-30
EP1030666A4 (en)	2002-10-16
CZ20001376A3 (cs)	2002-06-12
IL135581A0 (en)	2001-05-20
AR015966A1 (es)	2001-05-30
CN1306426A (zh)	2001-08-01
HUP0003792A3 (en)	2001-12-28
TR200001040T2 (tr)	2001-01-22
BR9814080A (pt)	2000-09-26
HUP0003792A2 (hu)	2001-10-28
NO20001847D0 (no)	2000-04-10

Legal Events

Date	Code	Title	Description
2002-11-19	EEER	Examination request
2004-10-18	FZDE	Discontinued

Publication	Publication Date	Title
AU740875B2 (en)	2001-11-15	Novel use of compounds for anti-pruritic activity
Golightly et al.	1988	Pharmaceutical excipients: adverse effects associated with inactive ingredients in drug products (Part I)
JPS62249923A (ja)	1987-10-30	パ−キンソン病、うつ病、ナルコレプシ−および脳器官精神症候群の抑制用薬剤およびその製造方法
JP2002527392A (ja)	2002-08-27	末梢的に作用する抗掻痒アヘン剤
ITMI20080395A1 (it)	2009-09-11	Formulazioni per il trattamento delle verruche e delle placche psoriatiche
WO2008091704A2 (en)	2008-07-31	Treatment of cushing's syndrome and autism
JPS62185014A (ja)	1987-08-13	複合調剤薬
JPWO2006041121A1 (ja)	2008-05-15	慢性皮膚疾患の治療および／または予防剤
US20030050329A1 (en)	2003-03-13	Synergistic combination comprising roflumilast and a PDE-3 inhibitor
JPS625913A (ja)	1987-01-12	ジヒドロピリジン含有製剤
UA123780C2 (uk)	2021-06-02	Лікування екземи кистей
JPH03204815A (ja)	1991-09-06	皮膚炎に対する治療用組成物
WO1999026613A1 (en)	1999-06-03	Aminoguanidine compositions for treating skin proliferative diseases
JP3276762B2 (ja)	2002-04-22	イソキノリン誘導体を含有する医薬組成物
JP2016517419A (ja)	2016-06-16	障害組織の全身および局所組合わせ処置
WO1989010143A1 (en)	1989-11-02	Certain paf antagonist antihistamine combinations and methods
MXPA00003775A (en)	2001-03-05	Novel use of compounds for anti-pruritic activity
US20060079513A1 (en)	2006-04-13	Methods and compositions including methscopolamine nitrate
JP2004026810A (ja)	2004-01-29	鼻炎用組成物
JPS6245525A (ja)	1987-02-27	脂質低下剤
EP0338010B1 (en)	1992-02-05	Pharmaceutical compositions for treatment of hyperproliferate skin disease
AU1563902A (en)	2002-03-28	Novel use of compounds for anti-pruritic activity
JPH0522687B2 (tr)	1993-03-30
AU5010193A (en)	1994-03-15	Methods of treating psoriasis employing substituted azaspiranes
EP0760663A1 (fr)	1997-03-12	Utilisation des derives de 2- 4-(azolylbutyl)-piperazinyl-methyl]-benzimidazole pour le traitement de la conjonctivite allergique

CA2306985A1 - Novel use of compounds for anti-pruritic activity - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (3)

Publications (1)

Family

ID=22051225

Family Applications (1)

Country Status (18)

Cited By (3)

Families Citing this family (15)

Family Cites Families (6)

Cited By (3)

Also Published As

Similar Documents

Legal Events